Prion Protein Found in Skin of CJD Patients
|
By LabMedica International staff writers Posted on 07 Dec 2017 |

Image: The FLUOstar Omega multi-mode microplate reader. A newly developed prion seeding assay called Real-Time Quaking Induced Conversion assay (RT-QuIC), scientists can now measure prion seeding at lower levels and in less than a few days in standard 96-well microplates (Photo courtesy of BMG Labtech).
Creutzfeldt-Jakob disease (CJD) is an incurable, and ultimately fatal, transmissible, neurodegenerative disorder in the family of prion diseases. Prion diseases originate when normally harmless prion protein molecules become abnormal and gather in clusters and filaments in the human body and brain.
Most people associate prion diseases with the brain, although scientists have found abnormal infectious prion protein in other organs, including the spleen, kidney, lungs and liver. Sporadic CJD (sCJC) is known to be transmissible by invasive medical procedures involving the central nervous system and cornea, but transmission via skin had not been a common concern.
A large team of scientists working with the National Institutes of Health’s Rocky Mountain Laboratories (Hamilton, MT. USA) explored the potential prion seeding activity and infectivity of skin from sCJD patients. Autopsy or biopsy skin samples from 38 patients (21 sCJD, two variant CJD (vCJD), and 15 non-CJD) were analyzed by Western blotting and real-time quaking-induced conversion (RT-QuIC) for PrPSc. Skin samples from two patients were further examined for prion infectivity by bioassay using two lines of humanized transgenic mice.
The tem reported that Western blotting revealed dermal PrPSc in one of five deceased sCJD patients and one of two vCJD patients. However, the more sensitive RT-QuIC assay detected prion seeding activity in skin from all 23 CJD decedents, but not in skin from any non-CJD control individuals (with other neurological conditions or other diseases) during blinded testing. Although sCJD patient skin contained ~103- to 105-fold lower prion seeding activity than did sCJD patient brain tissue, all 12 mice from two transgenic mouse lines inoculated with sCJD skin homogenates from two sCJD patients succumbed to prion disease within 564 days after inoculation.
Byron Caughey, PhD, a senior investigator who helped oversee the study said, “Our objective has always been to facilitate RT-QuIC testing using the most broadly available and least-invasive sample possible, whether that is blood, skin, nasal brushings, or other samples. This study used humanized mice with tissue extracts directly inoculated into the brain, so the system was highly primed for infection. There is no evidence that transmission can occur in real-world situations via casual skin contact.” The study was published on November 22, 2017, in the journal Science Translational Medicine.
Related Links:
National Institutes of Health Rocky Mountain Laboratories
Most people associate prion diseases with the brain, although scientists have found abnormal infectious prion protein in other organs, including the spleen, kidney, lungs and liver. Sporadic CJD (sCJC) is known to be transmissible by invasive medical procedures involving the central nervous system and cornea, but transmission via skin had not been a common concern.
A large team of scientists working with the National Institutes of Health’s Rocky Mountain Laboratories (Hamilton, MT. USA) explored the potential prion seeding activity and infectivity of skin from sCJD patients. Autopsy or biopsy skin samples from 38 patients (21 sCJD, two variant CJD (vCJD), and 15 non-CJD) were analyzed by Western blotting and real-time quaking-induced conversion (RT-QuIC) for PrPSc. Skin samples from two patients were further examined for prion infectivity by bioassay using two lines of humanized transgenic mice.
The tem reported that Western blotting revealed dermal PrPSc in one of five deceased sCJD patients and one of two vCJD patients. However, the more sensitive RT-QuIC assay detected prion seeding activity in skin from all 23 CJD decedents, but not in skin from any non-CJD control individuals (with other neurological conditions or other diseases) during blinded testing. Although sCJD patient skin contained ~103- to 105-fold lower prion seeding activity than did sCJD patient brain tissue, all 12 mice from two transgenic mouse lines inoculated with sCJD skin homogenates from two sCJD patients succumbed to prion disease within 564 days after inoculation.
Byron Caughey, PhD, a senior investigator who helped oversee the study said, “Our objective has always been to facilitate RT-QuIC testing using the most broadly available and least-invasive sample possible, whether that is blood, skin, nasal brushings, or other samples. This study used humanized mice with tissue extracts directly inoculated into the brain, so the system was highly primed for infection. There is no evidence that transmission can occur in real-world situations via casual skin contact.” The study was published on November 22, 2017, in the journal Science Translational Medicine.
Related Links:
National Institutes of Health Rocky Mountain Laboratories
Latest Molecular Diagnostics News
- Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers
- Genetic Marker Supports Anti-TNF Therapy Selection in Crohn’s Disease
- Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
- Genomic Test Guides Taxane-Based Chemotherapy Selection in Breast Cancer
- RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis
- AI Reasoning Model Generates Diagnostic Leads for Unresolved Rare Disease Cases
- Point-of-Care Molecular Test Detects Group A Strep in Minutes
- Spatial Map Guides Treatment Selection in Muscle-Invasive Bladder Cancer
- Point-of-Care PCR Panel Detects RSV, Influenza, and SARS-CoV-2 in Minutes
- Whole-Genome Sequencing Enables Genetic Diagnosis in Neurodevelopmental Disorders
- Genetic Testing Identifies High-Risk Patients with Inflammatory Bowel Disease
- Genomic Study Identifies Risk Regions for Intrahepatic Cholestasis of Pregnancy
- Genetic Testing and Surveillance Cuts Costs and Improves Survival in Li-Fraumeni Syndrome
- New Blood Test Predicts Organ-Specific Disease and Mortality Years in Advance
- Ancestry-Informed Genomics Advances Precision Cancer Prognosis
- Long-Read DNA Test Improves Diagnosis of Rare Genetic Diseases
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
Autoimmune disorders arise when immune responses target self-antigens, driving chronic inflammation and long-term morbidity. In primary Sjögren disease, inflammation of salivary and lacrimal glands leads... Read more
Airway Immune Signature May Predict Tuberculosis Progression Risk
Tuberculosis remains difficult to predict and prevent, despite widespread exposure worldwide. An estimated quarter of the global population has been infected with Mycobacterium tuberculosis, yet only a... Read moreMicrobiology
view channel
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read more
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read morePathology
view channel
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








